Results 211 to 220 of about 36,968 (260)
European Journal of Cancer, 1998 Some of the next articles are maybe not open access.
Related searches:
Related searches:
Bisphosphonates and Bisphosphonate Induced Osteonecrosis
Oral and Maxillofacial Surgery Clinics of North America, 2007Bisphosphonate-induced osteonecrosis of the jaws is the correct term for this real drug complication that most dental practitioners face. All nitrogen-containing bisphosphonates pose a risk, which is related to the route of administration, the potency of the bisphosphonate, and the duration of use.
Yoh, Sawatari, Robert E, Marx
openaire +2 more sources
Bisphosphonates and Osteoporosis
New England Journal of Medicine, 2002Osteoporosis affects millions of postmenopausal women in the United States alone. For white women who reach 50 years of age, the lifetime risk of vertebral fracture is about one in three, and that for hip fracture is one in six. One tenth to one fifth of the women who have a hip fracture die within a year after it occurs, and one quarter must move ...
openaire +4 more sources
Pharmacology of bisphosphonates
Bone, 2011Four decades of preclinical and clinical research of the pharmacology of bisphosphonates have generated data and concepts that have considerably improved their clinical use. However, despite this progress several pharmacological aspects relevant to bisphosphonate action on bone are still incompletely understood.
Serge Cremers, Socrates E Papapoulos
exaly +4 more sources
Bone, 2020
Bisphosphonates are first line agents used to treat osteoporosis and reduce fracture rate. They bind to areas of exposed calcium in the skeleton and cause osteoclast apoptosis, thereby leading to a reduction in remodelling rates. They are also used to decrease skeletal complications of some cancers including a reduction in bone metastases.
Jacqueline R, Center +2 more
openaire +2 more sources
Bisphosphonates are first line agents used to treat osteoporosis and reduce fracture rate. They bind to areas of exposed calcium in the skeleton and cause osteoclast apoptosis, thereby leading to a reduction in remodelling rates. They are also used to decrease skeletal complications of some cancers including a reduction in bone metastases.
Jacqueline R, Center +2 more
openaire +2 more sources
Bone, 2011
Bone metastases result in considerable morbidity, often affecting quality of life and independence over years, and may place complex demands on health care resources. The bisphosphonates have been shown to reduce skeletal morbidity in multiple myeloma and solid tumours affecting bone by 30-50%.
Robert E, Coleman, Eugene V, McCloskey
openaire +2 more sources
Bone metastases result in considerable morbidity, often affecting quality of life and independence over years, and may place complex demands on health care resources. The bisphosphonates have been shown to reduce skeletal morbidity in multiple myeloma and solid tumours affecting bone by 30-50%.
Robert E, Coleman, Eugene V, McCloskey
openaire +2 more sources
The kidney and bisphosphonates
Bone, 2011Bisphosphonates are eliminated from the human body by the kidney. Renal clearance is both by glomerular filtration and proximal tubular secretion. Bisphosphonates given rapidly in high doses in animal models have induced a variety of adverse renal effects, from glomerular sclerosis to acute tubular necrosis.
openaire +2 more sources
The American Journal of the Medical Sciences, 1997
The bisphosphonates are long-lived synthetic analogs of pyrophosphate, a natural, short-lived inhibitor of bone. Oral doses share similar qualities (ie, they inhibit bone resorption, poor absorption, and potential gastrointestinal irritants), but each one has a unique spectrum of potency and a probable mechanism of action.
openaire +2 more sources
The bisphosphonates are long-lived synthetic analogs of pyrophosphate, a natural, short-lived inhibitor of bone. Oral doses share similar qualities (ie, they inhibit bone resorption, poor absorption, and potential gastrointestinal irritants), but each one has a unique spectrum of potency and a probable mechanism of action.
openaire +2 more sources
[Corticotherapy and bisphosphonates].
Archives de pediatrie : organe officiel de la Societe francaise de pediatrie, 2005Corticotherapy and ...
openaire +2 more sources